Get alerts
Forecasted

Developing PBPK Model-Based Mechanistic IVIVCs for Long Acting Injectable Suspensions and Implants (U01) Clinical Trial Optional

View forecast on Grants.gov →Forecasted — not yet open

Posted
November 21, 2023
Closes
See announcement
Award ceiling
$300,000
Program funding
$600,000
Expected awards
2
Cost sharing
No
Instrument
Cooperative Agreement
Assistance listing
93.103
Category
Food and Nutrition, Health, Science and Technology and other Research and Development

Program funding history

Awards made under Assistance Listing 93.103 across FY2024–FY2026, from public federal spending records.

FY2024 obligated
$250.8M
FY2025 obligated
$213M
FY2026 (to date) obligated
$65.5M
Awards in window
920

Top recipients: The Critical Path Institute, National Environmental Health Association, Association of Food & Drug Officials, The Medical Device Innovation Consortium, Food & Agriculture, California Department of

Source: USAspending.gov · refreshed August 2026

Synopsis

The objective of this research proposal is to develop physiologically based pharmacokinetic (PBPK) model-based mechanistic in vitro in vivo correlations (IVIVCs) for two major types of long acting injectables (LAIs) such as crystalline suspensions and polymer-based implants by considering their distinct characteristics. The goal of the project is to develop a bottom-up mechanistic PBPK model for these two LAI categories by accounting for the influence of critical formulation attributes of each LAI drug product type to predict its in vivo release mechanism. The model formulation parameters and relevant physiology should be informed with suitable in vitro and in vivo experiments. A suitable preclinical animal model can be used to validate the PBPK model based IVIVCs for both LAI suspensions and polymer based implants.


The use of PBPK modelling provides a unique opportunity to understand how the physicochemical properties of drug molecules/polymer, implant specific properties, critical formulation attributes, and physiology, among other things, influence the in vivo release mechanisms of LAI drug products and their disposition characteristics. Moreover, once developed, a mechanistic PBPK model can help to define the 'safe space' for critical formulation attributes relevant to the reference listed drug (RLD) product, explain sources of PK variability and extrapolate predictions to human subjects by leveraging animal model data and by accounting for species-specific physiological differences.

Who can apply

Independent School DistrictsPublic Housing Authorities/Indian Housing AuthoritiesNative American Tribal Organizations (other than Federally recognized tribal governments)Faith-based or Community-based OrganizationsRegional OrganizationsNon-domestic (non-U.S.) Entities (Foreign Institutions

How to apply

Applications go through the official government listing. Grants Radar links you straight to the source — applying is free.

View on Grants.gov

Agency contact: Terrin Brown Grants Management Specialist · [email protected] · 240-402-7610

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe in one click.

The free edition carries one clearly labeled sponsor slot. No spam, ever. Privacy

Similar grants

Same-day alerts, matched to you

The free digest is weekly — the same list for everyone. Members get an alert the day a matching federal grant posts: we read every new Grants.gov posting and score it, personalized to your organization. Free for 30 days, then $19/mo founding rate locked for life — the rate holds while your subscription stays active (Terms). Card required, cancel any time before day 31.

See pricing